Showing results (221-230 of 302) with videos related to

Sort By:
Pageof 31
Leukemia & Lymphoma|July 22, 2016
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II studySamantha Pozzi, Massimo Gentile, Stefano Sacchi, et al.
Leukemia & Lymphoma|June 14, 2011
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantStefano Sacchi, Raffaella Marcheselli, Antonio Lazzaro, et al.
Hematological Oncology|October 22, 2021
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cellsSerena Matis, Martina Rossi, Lorenzo Brondolo, et al.
Non-Coding RNA|March 19, 2020
NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical OutcomeDomenica Ronchetti, Vanessa Favasuli, Paola Monti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2010
Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletionLaura Mosca, Sonia Fabris, Marta Lionetti, et al.
Blood|July 24, 2012
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myelomaSimona Blotta, Jana Jakubikova, Teresa Calimeri, et al.
American Journal of Hematology|December 23, 2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trialsMassimo Gentile, Valeria Magarotto, Massimo Offidani, et al.
Blood|October 15, 2011
The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemiaFortunato Morabito, Rosaria De Filippi, Luca Laurenti, et al.
BMC Medical Genomics|September 6, 2013
Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemiaDomenica Ronchetti, Laura Mosca, Giovanna Cutrona, et al.
European Journal of Haematology|May 25, 2010
Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletionEsther N Oliva, Maria Cuzzola, Francesco Nobile, et al.
Pageof 31